Mebendazole Essentials: Guide for Integrative Use (Module 1, Course 3)

Course Overview

Repurposed Medications in Oncology: A Study Guide for Doctors (Module 1, Course 3 – Mebendazole) explores the growing body of research surrounding mebendazole as an anti-cancer therapy. Originally FDA-approved to treat parasitic infections, this drug has gained interest for its ability to disrupt microtubule polymerization, induce apoptosis, and modulate the immune response—key processes involved in cancer progression.

This guide provides a scientific and clinical overview of mebendazole’s role in glioblastomas, lung cancer, colorectal cancer, and other difficult-to-treat malignancies.

Who is This Course For?

• Oncologists and Cancer Researchers
• Integrative and Functional Medicine Doctors
• Medical Students and Healthcare Practitioners
• Pharmacists and Clinical Scientists

What You Will Learn

• How mebendazole interferes with cancer cell division and metastasis
• Clinical research supporting its use in glioblastoma and other aggressive tumors
• The role of mebendazole in angiogenesis inhibition, immune modulation, and chemotherapy resistance reversal
• Safe dosing protocols and laboratory monitoring for clinical use
• How to incorporate mebendazole into integrative oncology treatment plans

Course Structure & Content

• Chapter 1: Introduction to Mebendazole – Discovery and FDA Approval
• Chapter 2: Mechanisms of Action and Microtubule Disruption
• Chapter 3: Preclinical and Clinical Research Findings
• Chapter 4: Pharmacokinetics, Drug Interactions, and Metabolism
• Chapter 5: How Mebendazole Affects the Hallmarks of Cancer
• Chapter 6: Dosing, Toxicity, and Laboratory Monitoring
• Chapter 7: Stacking Therapies – Mebendazole with Chemotherapy, Radiation, and Immunotherapy
• Chapter 8: Key Takeaways and Next Steps in Research
• Chapter 9: Self-Guided Quiz for Medical Professionals
• Chapter 10: FAQ – Addressing Common Questions About Mebendazole